Beacon Therapeutics Begins LANDSCAPE Trial With First Patient Dosed In laru-zova Study For X-Linked Retinitis Pigmentosa

Beacon Therapeutics Holdings Limited, a clinical-stage biotechnology company focused on developing treatments to preserve and restore vision in patients with rare and common eye diseases, announced that the first patient has been treated in its LANDSCAPE clinical trial. LANDSCAPE is an open-label study designed to evaluate the safety of administering laru-zova, also known as laruparetigene zovaparvovec, in both eyes. Laru-zova is an investigational gene therapy being developed as a potential best-in-class treatment for patients with X-linked retinitis pigmentosa (XLRP).

The Company explained that the start of the LANDSCAPE trial follows the completion of patient enrollment earlier this year in its registrational VISTA study of laru-zova in XLRP. The new study is intended to further assess the safety of bilateral dosing when treatment is given to both eyes within a short timeframe. According to Beacon, this represents an important step toward expanding treatment options for patients affected by this severe inherited retinal disease and adds to the Company’s growing clinical experience with laru-zova.

The primary goal of the LANDSCAPE trial is to evaluate the safety of laru-zova when administered bilaterally using subretinal injection. In addition to safety, the study will assess changes in visual function following treatment in both eyes. The trial is enrolling male patients between the ages of 12 and 50 who have a confirmed diagnosis of XLRP, with clinical sites located across the United States.

X-linked retinitis pigmentosa is a genetic eye disorder that causes progressive vision loss and often leads to legal blindness. There are currently no approved treatments for the condition. XLRP is most commonly caused by mutations in the RPGR gene and accounts for approximately 10 percent of the estimated 100,000 people living with retinitis pigmentosa in the United States. Laru-zova is designed to address the underlying genetic cause of the disease by delivering a functional copy of the RPGRORF15 gene, with the goal of restoring normal function in both rod and cone photoreceptor cells.

The LANDSCAPE study builds on encouraging clinical data generated in earlier trials of laru-zova. Interim results from the Phase 2 DAWN and SKYLINE studies, which were presented at the EURETINA 2025 congress, showed sustained improvements in multiple measures of visual function, including low-luminance visual acuity and microperimetry. In these studies, laru-zova was generally well tolerated, with safety observed through up to 36 months in the SKYLINE trial and at least nine months in the DAWN trial. Beacon also recently completed enrollment in the pivotal VISTA trial of laru-zova and expects to report topline results in the second half of 2026.